Dossou, A.S.; Kang, S.; Kalhoro, T.; Castro-Echeverry, E.; Horton, N.C.
Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients. Diagnostics 2025, 15, 2447.
https://doi.org/10.3390/diagnostics15192447
AMA Style
Dossou AS, Kang S, Kalhoro T, Castro-Echeverry E, Horton NC.
Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients. Diagnostics. 2025; 15(19):2447.
https://doi.org/10.3390/diagnostics15192447
Chicago/Turabian Style
Dossou, Akpedje Serena, Serena Kang, Tahira Kalhoro, Eduardo Castro-Echeverry, and Nathan C. Horton.
2025. "Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients" Diagnostics 15, no. 19: 2447.
https://doi.org/10.3390/diagnostics15192447
APA Style
Dossou, A. S., Kang, S., Kalhoro, T., Castro-Echeverry, E., & Horton, N. C.
(2025). Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients. Diagnostics, 15(19), 2447.
https://doi.org/10.3390/diagnostics15192447